CELLCEUTIX CORP COM STK USD0.0001 (CTIX)

0.75
0.01 1.01
OTC
Prev Close 0.74
Open 0.75
Day Low/High 0.70 / 0.76
52 Wk Low/High 0.63 / 1.55
Volume 191.58K
Exchange OTC
Shares Outstanding 131.38B
Market Cap 105.10M
Div & Yield N.A. (N.A)

Latest News

Cellceutix Reports Very Encouraging Interim Analysis Of Phase 2 Drug Candidate Brilacidin For Severe Oral Mucositis (OM) In Head And Neck Cancer Patients; High Potential For Preventative Treatment

Study showed a markedly reduced rate of Severe OM (WHO Grade = 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Cellceutix Releases Favorable Topline Findings As Part Of Interim Analysis Of Phase 2 Drug Candidate Brilacidin For The Treatment Of Inflammatory Bowel Disease

Study results, through the first two cohorts of patients treated, support Brilacidin as a novel and promising anti-inflammatory drug candidate

Cellceutix's Phase 2 Drug Candidate Brilacidin Emerging As A Potential Novel Non-Biologic Therapy In Treating Inflammatory Bowel Disease

Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Cellceutix Investors See Red Flags in Drug Study

Cellceutix Investors See Red Flags in Drug Study

Does Cellceutix have something to hide?

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Management to provide Clinical, Regulatory and Financial Updates